March 25, 2026International Journal of Urology1 citations
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
To evaluate the effect of corticosteroid premedication on toxicity and survival rates in patients treated with enfortumab vedotin for urothelial carcinoma.
Conducted an observational study of patients receiving enfortumab vedotin.
Analyzed the correlation between corticosteroid premedication and reported skin toxicities.
Monitored survival outcomes in relation to premedication use.
Corticosteroid premedication significantly reduced skin toxicities during treatment.
Survival impact of corticosteroid premedication remains uncertain and needs further validation.
Abstract
Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.